We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Biovail To Pay $24.6M Over Cardizem Marketing

Law360 (May 16, 2008, 12:00 AM EDT) -- Biovail Corp.’s pharmaceutical subsidiary has agreed to shell out $24.6 million to resolve criminal charges brought by the U.S. Department of Justice related to Biovail's blood pressure drug Cardizem LA.

The Toronto-based firm said Friday its New Jersey unit, Biovail Pharmaceuticals Inc., will also plead guilty to charges that it paid people to induce them to purchase or prescribe the medication.

Biovail, which is Canada’s biggest publicly traded pharmaceutical firm, said the agreement releases it from any criminal liability and allows the company to continue to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.